Pharma Mar, S.A. (PHMMF)
OTCMKTS · Delayed Price · Currency is USD
91.22
0.00 (0.00%)
Aug 10, 2025, 8:00 PM EDT
CTI BioPharma Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 42.01 | 26.13 | 1.14 | 49.36 | 92.86 | 137.26 | Upgrade |
Depreciation & Amortization | 6.61 | 5.72 | 4.72 | 4.89 | 4.56 | 4.33 | Upgrade |
Other Amortization | 1.05 | 1.05 | 1.03 | 1.01 | 1.03 | 2.88 | Upgrade |
Loss (Gain) From Sale of Assets | -0.35 | -0.84 | 1.93 | -0.01 | 0.03 | 0.03 | Upgrade |
Asset Writedown & Restructuring Costs | -0.78 | -0.28 | -1.75 | 1.48 | -0.18 | 0.37 | Upgrade |
Stock-Based Compensation | 0.01 | - | 0.3 | 0.39 | 0.34 | 0.27 | Upgrade |
Provision & Write-off of Bad Debts | - | - | - | - | - | 0.02 | Upgrade |
Other Operating Activities | 9.47 | 6 | 14.09 | 9.42 | -11.55 | 5.84 | Upgrade |
Change in Accounts Receivable | -29.8 | -7.32 | 1.78 | 21.61 | -26.76 | -12.63 | Upgrade |
Change in Inventory | -4.23 | -12.68 | -11.54 | -17.21 | 1.4 | -3.03 | Upgrade |
Change in Accounts Payable | 5.86 | 11.23 | 3.39 | 1.79 | 7.19 | 4.65 | Upgrade |
Change in Unearned Revenue | -25.57 | -24.93 | -23.2 | - | - | - | Upgrade |
Change in Other Net Operating Assets | 4.52 | 1.95 | -5.34 | -34.41 | -43.23 | 138.95 | Upgrade |
Operating Cash Flow | 8.8 | 6.03 | -13.45 | 38.32 | 25.68 | 278.94 | Upgrade |
Operating Cash Flow Growth | - | - | - | 49.24% | -90.80% | - | Upgrade |
Capital Expenditures | -7.02 | -15.02 | -14.81 | -8.85 | -7.8 | -3 | Upgrade |
Sale of Property, Plant & Equipment | 0.41 | 0.89 | - | 0.01 | - | - | Upgrade |
Sale (Purchase) of Intangibles | -0.5 | -0.5 | -1.15 | - | - | - | Upgrade |
Investment in Securities | 12.94 | 15.66 | -27.09 | 19.72 | 26.28 | -116.01 | Upgrade |
Investing Cash Flow | 5.83 | 1.03 | -43.05 | 10.88 | 18.47 | -119.01 | Upgrade |
Long-Term Debt Issued | - | 15.41 | 7.2 | 1.54 | 5.83 | 0.83 | Upgrade |
Total Debt Issued | 17.26 | 15.41 | 7.2 | 1.54 | 5.83 | 0.83 | Upgrade |
Long-Term Debt Repaid | - | -9.56 | -8.36 | -10.2 | -15.27 | -32.37 | Upgrade |
Total Debt Repaid | -7.27 | -9.56 | -8.36 | -10.2 | -15.27 | -32.37 | Upgrade |
Net Debt Issued (Repaid) | 9.98 | 5.86 | -1.15 | -8.66 | -9.44 | -31.54 | Upgrade |
Issuance of Common Stock | 18.24 | 18.91 | 18.61 | 57.23 | 33.55 | 30.37 | Upgrade |
Repurchase of Common Stock | -26.08 | -18.63 | -37.9 | -50.18 | -40.66 | -63.71 | Upgrade |
Common Dividends Paid | -13.95 | -11.42 | -11.69 | -11.76 | -10.87 | -8.82 | Upgrade |
Other Financing Activities | -0.07 | -0.07 | - | - | - | -0.12 | Upgrade |
Financing Cash Flow | -11.87 | -5.35 | -32.14 | -13.37 | -27.42 | -73.82 | Upgrade |
Foreign Exchange Rate Adjustments | -0.48 | 1.51 | -1.16 | 0.64 | 0.4 | -7.54 | Upgrade |
Net Cash Flow | 2.27 | 3.22 | -89.79 | 36.47 | 17.14 | 78.57 | Upgrade |
Free Cash Flow | 1.78 | -8.99 | -28.25 | 29.47 | 17.87 | 275.94 | Upgrade |
Free Cash Flow Growth | - | - | - | 64.87% | -93.52% | - | Upgrade |
Free Cash Flow Margin | 0.94% | -5.14% | -17.87% | 15.01% | 7.78% | 102.21% | Upgrade |
Free Cash Flow Per Share | - | -0.51 | -1.58 | 1.63 | 0.99 | 15.06 | Upgrade |
Cash Interest Paid | 2.54 | 2.47 | 2.42 | 2.38 | 3.37 | 3.12 | Upgrade |
Cash Income Tax Paid | - | -23.26 | -16.59 | -2.72 | 7.86 | 9.65 | Upgrade |
Levered Free Cash Flow | -15.89 | -20.15 | -12.59 | 33.11 | 4.75 | 128.41 | Upgrade |
Unlevered Free Cash Flow | -13.33 | -18.61 | -11.08 | 34.6 | 6.86 | 130.36 | Upgrade |
Change in Working Capital | -49.22 | -31.75 | -34.91 | -28.22 | -61.41 | 127.94 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.